CYP1B1-IN-4
Code | Size | Price |
---|
TAR-T73040-5mg | 5mg | £115.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T73040-1mL | 1 mL * 10 mM (in DMSO) | £131.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T73040-10mg | 10mg | £142.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T73040-25mg | 25mg | £213.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T73040-50mg | 50mg | £303.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T73040-100mg | 100mg | £414.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
CYP1B1-IN-4 is a selective CYP1B1 inhibitor with an IC50 value of 0.2 nM.CYP1B1-IN-4 is a 2,4-diarylthiazole compound with potential anticancer activity and low cytotoxicity, and is stable in human and rat liver microsomes.
CAS:
2685779-55-7
Molecular Weight:
322.38
Pathway:
Metabolism
Purity:
0.98
SMILES:
N#CC=1C=CC(=CC1)C=2N=C(SC2)C=3C=CC(OC)=CC3OC
Target:
P450
References
Hachey AC, et al. Design of Cytochrome P450 1B1 Inhibitors via a Scaffold-Hopping Approach. J Med Chem. 2023 Jan 12;66(1):398-412.